Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN)

OKYO Pharma (NASDAQ:OKYO) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Earnings & Valuation

This table compares OKYO Pharma and enGene”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
enGene	N/A	N/A	-$99.92 million	N/A	N/A

Profitability

This table compares OKYO Pharma and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
enGene	N/A	-66.38%	-56.00%

Insider and Institutional Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 13.7% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for OKYO Pharma and enGene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
enGene	0	0	9	1	3.10

OKYO Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 573.08%. enGene has a consensus target price of $30.38, suggesting a potential upside of 251.16%. Given OKYO Pharma’s higher probable upside, equities analysts clearly believe OKYO Pharma is more favorable than enGene.

Volatility & Risk

OKYO Pharma has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.76, meaning that its share price is 176% less volatile than the S&P 500.

Summary

OKYO Pharma beats enGene on 6 of the 10 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.